← Back

Aurora Cannabis Inc

ACBUSD
4.49-26.9%1Y · USD

Aurora Cannabis Inc. produces, distributes, and sells cannabis products in Canada and internationally through its subsidiaries. Its offerings include pharmaceutical-grade cannabis, medical and consumer cannabis, and a range of formats such as oils, capsules, edibles, vaporizers, dried and fresh cannabis, plants, seeds, extracts, flowers, inhalable extracts, pastilles, concentrates, and topicals. The company also provides patient counseling and outreach services, and operates pharmacy activities. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty's, Whistler, and WMMC. Founded in 2013, Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Country
Price · split & dividend adjusted

Why is Aurora Cannabis Inc (ACB) moving?

Latest
▲2

Curaleaf's hostile bid for Aurora dominates the period

  • International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.

    Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.

  • Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.

    The bid is the single biggest force moving ACB's price this period.

  • Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.

    Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

News & notes moving ACB
Canada
ACB2

Aurora Keeps Take No Action Stance as Curaleaf Has Yet to File Revised Hostile Bid

Aurora Cannabis said it is maintaining its recommendation that shareholders take no action on Curaleaf's hostile take-over bid because Curaleaf has yet to file the Notice of Variation and Change needed to formally revise the offer. Curaleaf has stated an intention to offer revised implied consideration of US$5.00 per Aurora share, consisting of 0.4013 subordinate voting shares of Curaleaf plus US$1.00 in cash per Aurora share, but Aurora said it has not received the materials required for a full evaluation. Executive Chairman and CEO Miguel Martin said the Special Committee of independent directors will review any formal revised offer once received with the same rigorous, independent and disciplined process applied previously, and the Board will communicate its recommendation once that review is complete. Aurora said its application to the Alberta Securities Commission delivered results, as Curaleaf has now agreed to amend its bid circular to include required pro forma financial statements and to extend the expiry time for the Hostile Bid to 11:59pm Mountain Time on December 4, 2026. Aurora shareholders will have until at least December 4, 2026 to consider their options, and the Board's formal recommendation will be provided through a news release and Directors' Circular within 15 days in accordance with applicable securities laws.
ACB · Regulation · Neutral Aurora maintains 'take no action' stance on Curaleaf's hostile bid, which has yet to be formally revised, and won a regulatory outcome at the Alberta Securities Commission extending the bid deadline.
Curaleaf Holdings · Regulation · Neutral Curaleaf's hostile bid for Aurora remains unfiled as a formal revised offer and it agreed to amend its bid circular and extend the expiry to December 4, 2026.
Read original ↗
PR Newswire·5dRead more →
United StatesCanada
ACB▼

Aurora and Curaleaf Trade Barbs in Hostile Takeover Battle

The hostile takeover battle between Curaleaf and Aurora has escalated as both companies publicly trade accusations. Curaleaf, which has made a $4 per share offer worth about $272 million, published a rebuttal to Aurora's directors' circular urging shareholders to reject the bid. Curaleaf's CEO Boris Jordan accused Aurora of misleading narratives and failing to engage in negotiations, while Aurora's CEO Miguel Martin urged shareholders to focus on the value they already own. Aurora highlights its $149 million in cash and no debt, contrasting with Curaleaf's roughly $1 billion in debt and lease liabilities. Curaleaf argues its offer represents a 45% premium, or 110% excluding Aurora's cash, and notes that Aurora insiders own about 1% of the company but could receive roughly 10% of the deal value. The bid, open since Aug. 18, expires Dec. 1, and the core of the deal is Aurora's EU-GMP certified facilities for exporting cannabis to European medical markets.
ACB · Capital · Negative Aurora is the target of a hostile takeover bid at $4/share, with Curaleaf highlighting its debt and urging rejection.
Curaleaf Holdings · Capital · Positive Curaleaf is pursuing a hostile takeover of Aurora, offering a 45% premium and expanding into EU medical cannabis markets.
Read original ↗
Yahoo Finance·31dRead more →
United StatesCanada
ACB▲2

Curaleaf Launches $260 Million Takeover Bid for Aurora Cannabis

Curaleaf Holdings has begun a takeover bid for Canadian cannabis retailer Aurora Cannabis, valuing Aurora at around $260 million. Under the proposal, Aurora shareholders would receive 0.3463 Curaleaf shares and $0.75 in cash per Aurora share, for a total consideration of $4 per share, capped at $5 per share if Curaleaf's stock rises above a set level. Aurora closed Friday at $3.94. The move would improve Curaleaf's global footprint and leverage its operational expertise to sell Aurora's high-quality products, despite Aurora's first-quarter fiscal 2027 EPS loss of $0.07 and $93.7 million in debt. The expected rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act may prompt other mergers and acquisitions, as larger companies will pay less in taxes and have more money to expand. Green Thumb Industries, one of the most profitable U.S. cannabis retailers with more than 140 stores across 14 markets, is likely to pursue smaller, single-state operators or distressed assets in limited-license states rather than megamergers, given its disciplined approach and $283.6 million in cash at the end of the second quarter.
ACB · Capital · Positive Curaleaf launches $260M takeover bid for Aurora at $4/share, a premium to Friday's close.
Green Thumb Industries Inc. · Capital · Neutral Mentioned as likely to pursue smaller acquisitions, not directly impacted by this news.
Read original ↗
The Motley Fool·48dRead more →
GlobalUnited StatesAustraliaCanadaIsrael
ACB▲

Workday, Diversified Energy, Aurora Cannabis lead week's key deals

Several major acquisition deals were reported across sectors this week. Workday soared 19% on a report that private equity firm Silver Lake is in talks to buy the software company. Diversified Energy is in advanced talks to acquire Elliott Investment Management-backed oil and gas company Birch Resources for more than $1.7 billion in cash. EQT Infrastructure offered to buy Cleanaway Waste Management in a deal that values the Australian listed firm at about A$6.9 billion, or $4.9 billion. H.B. Fuller said it received an unsolicited proposal from Ancora Holdings to buy its building adhesives solutions business for $1.1 billion to $1.2 billion in cash. Aurora Cannabis soared 21% after Curaleaf Holdings said it plans to make a $4 per share takeover bid, with Curaleaf rising 6.7%. H&R Real Estate Investment Trust agreed to be acquired by GO Residential Real Estate Investment Trust and a consortium including Blackstone, Crestpoint, PSP Investments and a company controlled by members of the family of H&R CEO Tom Hofstedter in a deal valued at about C$6.7 billion, including assumed debt. Israeli AI startup Decart is in advanced talks to be sold to a major tech firm for $6 billion to $7 billion. Jazz Pharmaceuticals announced it will acquire privately held Actio Biosciences for $820 million upfront and up to $500 million in potential milestones.
ACB · Capital · Positive Curaleaf plans $4/share takeover bid, stock soars 21%
DEC · Capital · Positive In advanced talks to acquire Birch Resources for over $1.7B cash
FUL · Capital · Positive Received unsolicited proposal from Ancora to buy building adhesives business for $1.1-1.2B
JAZZ · Capital · Positive Announced acquisition of Actio Biosciences for $820M upfront plus milestones
WDAY · Capital · Positive Silver Lake in talks to buy company, stock soars 19%
Cleanaway Waste Management Ltd · Capital · Positive EQT Infrastructure offered to buy Cleanaway Waste Management at A$6.9 billion, a premium acquisition proposal.
Read original ↗
Seeking Alpha·56dRead more →
CanadaGermany
ACB▲

Aurora Cannabis Q1 2027 Earnings Call Transcript

Aurora Cannabis reported fiscal first quarter 2027 results for the period ending June 30, 2026, with net revenue of $67.6 million and adjusted gross margin of 58%. International medical cannabis net revenue rose 17% to $43 million, driven by strong performance in Germany, and about 64% of total net revenue was generated outside of Canada, up from 50% last year. Adjusted EBITDA was $3.4 million compared to $10.8 million in the prior year, while adjusted net income was $3.8 million compared to $6.6 million last year. The company ended the quarter with nearly $150 million in cash, cash equivalents, and short-term investments with no debt. Aurora reaffirmed its fiscal 2027 outlook and expects revenue and adjusted EBITDA to be substantially higher in the fiscal second quarter than in the first quarter.
ACB · Capital · Positive Aurora reported Q1 FY2027 results with revenue and adjusted EBITDA, reaffirmed outlook, and highlighted strong international growth.
Read original ↗
The Motley Fool·59dRead more →
United StatesIranPanama
Defense & Geopolitical Fragmentation▲

Gold surges to two-month high, home sales decline, Aurora Cannabis targeted

Spot gold climbed to $4,395 an ounce, its highest level since June 5, while U.S. existing home sales fell 1.7% month-over-month in July to an annualized rate of 4.06 million units. Aurora Cannabis shares soared 15% in premarket trading after Curaleaf Holdings announced a $4 per share public takeover bid, a 38% premium to Monday's close. A U.S. military helicopter struck a Panama-flagged vessel attempting to run the American blockade of Iranian ports after the crew ignored warnings, with no casualties reported. The SPDR Gold Shares ETF recorded $637 million in total inflows on Wednesday, its biggest single-day haul since June 18, pushing August inflows above $1.4 billion and positioning the fund for its first monthly net inflow since February.
About megatrends
Defense & Geopolitical Fragmentation › Defense Primes — United States Geopolitics
ACB · Capital · Positive Curaleaf announced a $4 per share takeover bid, a 38% premium.
Curaleaf Holdings · Capital · Positive Curaleaf announced a $4 per share takeover bid for Aurora Cannabis.
GOLD · Monetary · Positive Gold surged to a two-month high amid geopolitical tensions and ETF inflows.
Read original ↗
Seeking Alpha·60dRead more →
Canada
ACB▲

Aurora Cannabis International Medical Revenue Rises 17% in First Quarter

Aurora Cannabis reported a 17% increase in international medical cannabis revenue to C$43.3 million in its fiscal first quarter ended June 30, 2026, even as total net revenue fell 9% to C$67.6 million due to a Canadian reimbursement cut and the wind-down of its consumer business. Adjusted gross margin reached 58%, the high end of the company's full-year guidance, while adjusted EBITDA declined to C$3.4 million from C$10.8 million a year earlier. The company's newly acquired Safari facility contributed positively to adjusted EBITDA in its first quarter and received a three-year EU-GMP certification, expanding internal supply for high-margin international markets. Management expects higher second-quarter revenue and adjusted EBITDA, and Street estimates point to a return to growth and positive free cash flow in fiscal 2028. Aurora ended the quarter with C$149.1 million in cash, restricted cash, and short-term investments and no debt.
ACB · Demand · Positive International medical revenue rose 17% to C$43.3M, and the Safari facility received EU-GMP certification, expanding high-margin supply.
Read original ↗
ExecEdge·63dRead more →
ACB▼

Cronos Group Q1 Revenue Jumps 40% but Zacks Rates Stock a Sell

Cronos Group reported first-quarter 2026 net revenue of $45.2 million, a 40% year-over-year increase driven by higher cannabis flower sales in Israel, Canada, and other international markets. Gross profit rose 39% to $19.2 million, while its Canadian brands posted 18% retail sales growth, far outpacing the industry's 2% gain. Despite the strong quarter, Zacks Investment Research assigns Cronos a Zacks Rank of 4, or Sell, citing intense competition from peers such as Aurora Cannabis and Tilray Brands and caution about the pace at which strategic initiatives will translate into sustained earnings growth. The company's shares have risen more than 2% year to date, compared with a nearly 7% decline for the industry.
CRON · Demand · Positive Cronos reported 40% revenue growth driven by higher cannabis flower sales in Israel, Canada, and other international markets, and its Canadian brands outpaced industry growth.
ACB · Competition · Negative Article mentions Aurora Cannabis as a competitor in a market where Cronos is gaining share, implying competitive pressure on Aurora.
TLRY · Competition · Negative Article mentions Tilray as a competitor in a market where Cronos is gaining share, implying competitive pressure on Tilray.
Read original ↗
Zacks Investment Research·108dRead more →